FDA Approves Inotuzumab Ozogamicin for Relapsed or Refractory B-cell Precursor ALL
Aug 16
2017
The U.S. Food and Drug Administration approved inotuzumab ozogamicin (BESPONSA, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
